Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EN-SEMBLE post-trastuzumab deruxtecan treatment cohort in breast cancer
jRCT1030220506Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Distribution of post-treatment regimen, Progression-free survival and 10 more. Started Dec 2022; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT1030220506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030220506.